PFO tamponade is an effective and safe vitreous substitute

Article

The perfluoro-n-octane (PFO) tamponade is a safe and effective short-term vitreous substitute in primary rhegmatogenous retinal detachment repair

The perfluoro-n-octane (PFO) tamponade is a safe and effective short-term vitreous substitute in primary rhegmatogenous retinal detachment repair, reveals a study in Retina

Dr Ryan Rush and his team, Sydney Eye Hospital, Australia, retrospectively analysed the charts of 39 eyes at 2-24 postoperative months after primary PFO retention. The second replacement was evaluated for anatomical attachment rates, visual acuity gain and postoperative complications.

The results demonstrated that 33 of 39 eyes had four or more retinal breaks - 31 of these eyes had at least one inferior break and 12 presented with preoperative proliferative vitreoretinopathy.

PFO was retained without posturing and all eyes showed full anatomical retinal attachment after primary vitrectomy for at least 7-17 days. The final anatomical success rate was 92.4% after perfluoropropane gas or siicone oil PFO exchange.

Visual acuity improved from 2.07 ± 0.86 to 0.76 ± 0.79 logarithm of the minimum angle of resolution in macula-off and 0.11 ±0.08 to 0.12 ± 0.09 logarithm of the minimum angle of resolution in macula-on rhegmatogenous retinal detachment eyes.

Posterior capsular opacification was greatly increased due to PFO retention, without affecting the final retinal attachment success rate. The highest reattachment rates were made when perfluoropropane or silicone oil was swapped for PFO.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.